Memorial Ataşehir Hospital, Clinic of Pediatrics, İstanbul, Turkey.
Istanbul Health and Technology University, Department of Pediatrics, İstanbul, Turkey.
Hum Vaccin Immunother. 2021 Nov 2;17(11):3876-3880. doi: 10.1080/21645515.2021.1953344. Epub 2021 Jul 29.
The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15-136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202-10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8-15547 AU/mL, = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals.
灭活的 SARS-CoV-2 疫苗（科兴）对既往自然感染者的效果尚不明确。本研究旨在比较既往自然感染者和未感染者健康工作者（HCW）接种科兴疫苗的免疫原性和不良反应。所有 HCW 均于 28 天间隔接受两剂科兴疫苗（600U/0.5ml）肌肉注射。接种后第 7 天通过在线问卷或电话获取不良反应情况。接种第二剂疫苗四周后检测针对 SARS-CoV-2 刺突蛋白受体结合域（RBD）的抗体水平。本研究共纳入 103 例既往自然感染者和 627 例未感染者。既往自然感染者接种首剂疫苗的中位时间为首次鼻咽拭子 SARS-CoV-2 阳性后 64 天（范围：15-136 天）。既往自然感染者中，41 例（40%）无症状，52 例（50%）为轻度上呼吸道感染，10 例（10%）为肺炎，仅有 6 例（5%）住院。与未感染者相比，既往感染者无论接种第一剂还是第二剂疫苗后报告的任何不良反应均无差异。在 103 例既往感染者中，有 50 例（51%）获得了 RBD 抗体滴度，在 627 例未感染者中，有 142 例（23%）获得了 RBD 抗体滴度。既往自然感染者的 RBD 抗体滴度明显高于未感染者（中位数 1220 AU/ml，范围：202-10328 AU/ml）（中位数：913 AU/ml，范围：2.8-15547 AU/ml， =.032）。科兴疫苗接种安全，并可能在既往自然感染者中引发更高的抗体反应。
